Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenofibrate/simvastatin - AbbVie

Drug Profile

Fenofibrate/simvastatin - AbbVie

Alternative Names: Cholib; Simvastatin/fenofibrate; Treakol

Latest Information Update: 06 Oct 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fournier Pharma
  • Developer AbbVie; Fournier Pharma
  • Class Antihyperlipidaemics; Butyric acids; Naphthalenes; Propionates
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Oct 2015 No recent reports of development identified - Phase-III for Hyperlipidaemia in Russia, Mexico and Argentina (PO)
  • 26 May 2015 No recent reports of development identified - Phase-III for Hyperlipidaemia in Ukraine, Australia, New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top